Table 2. The summarized data of clinical and pathological parameters from all included studies in the meta-analysis.
| Gender | Smoking history | TNM Stage | Metastasis | Lymph node metastasis | Cancer type(nuclear positive) | Histological differentiation | Treatment | Response rate | OS | PFS | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No.of Studies | First Author | Year | NRF2 expression | male | Female | Never | Current/former | I + II | III+ IV | M0 | M1 | Yes | No | Squamous cell carcinomas | Adenocarcinomas | Well and moderately | Poorly/undifferentiated | Yes | No | CR and PR | SD and PD | HR estimate | 95% CI | HR estimate | 95% CI |
| 1 | Luisa M. Solis | 2010 | High | 157 | 147 | 50 | 253 | - | - | - | - | - | - | 43 | 34 | - | - | 34 | 20 | - | - | 1.747 | 1.12–2.726 | 2.31 | 1.53–3.47 |
| Low | - | - | - | - | - | - | - | - | - | - | 79 | 154 | - | - | 55 | 39 | - | - | - | - | - | - | |||
| 2 | Haihong Yang | 2011 | High | 26 | 8 | 12 | 22 | - | - | - | - | - | - | 5 | 29 | 8 | 17 | 24 | 10 | 4 | 13 | 0.3 | 0.138–0.652 | 0.174 | 0.062–0.448 |
| Low | 14 | 12 | 13 | 13 | - | - | - | - | - | - | 6 | 20 | 8 | 9 | 19 | 7 | 18 | 8 | - | - | - | - | |||
| 3 | Daisuke Inoue | 2012 | High | 31 | 6 | - | - | - | - | - | - | 14 | 23 | 11 | 25 | 27 | 10 | - | - | - | - | 5 | 2.4–10.6 | - | - |
| Low | 47 | 25 | - | - | - | - | - | - | 21 | 51 | 20 | 47 | 49 | 23 | - | - | - | - | - | - | - | - | |||
| 4 | Heta Merikallio | 2012 | High | - | - | - | - | - | - | - | - | - | - | 71 | 57 | - | - | - | - | - | - | 1.49* | 1.23–1.79 | - | - |
| Low | - | - | - | - | - | - | - | - | - | - | 36 | 29 | - | - | - | - | - | - | - | - | - | - | |||
| 5 | Ming-Hsien Chien | 2015 | High | 32 | 55 | - | - | 33 | 54 | 62 | 25 | 55 | 32 | - | - | - | - | - | - | - | - | - | - | - | - |
| Low | 32 | 48 | - | - | 47 | 33 | 64 | 16 | 37 | 43 | - | - | - | - | - | - | - | - | - | - | - | - | |||
| 6 | Xiang Zhu a | 2014 | High | 6 | 18 | 16 | 8 | - | - | - | - | - | - | - | - | 19 | 5 | 24 | 0 | 13 | 11 | 1.352 | 0.487–3.752 | - | - |
| Low | 4 | 3 | 4 | 3 | - | - | - | - | - | - | - | - | 7 | 0 | 7 | 0 | 6 | 1 | - | - | - | - | |||
| 6` | Xiang Zhu b | 2014 | High | 3 | 9 | 8 | 4 | - | - | - | - | - | - | - | - | 9 | 3 | 12 | 0 | 0 | 12 | 5.449 | 1.065–27.873 | 5.944 | 1.912–18.483 |
| Low | 7 | 12 | 12 | 7 | - | - | - | - | - | - | - | - | 17 | 2 | 19 | 0 | 19 | 0 | - | - | - | - | |||
| 7 | Joo-Heon Kim | 2007 | High | 23 | 32 | 14 | 41 | - | - | - | - | - | - | 16 | 33 | 30 | 24 | - | - | - | - | - | - | - | - |
| Low | 21 | 13 | 3 | 31 | - | - | - | - | - | - | 15 | 15 | 12 | 20 | - | - | - | - | - | - | - | - | |||
| 8 | Tinghua Hu | 2014 | High | 35 | 7 | 21 | 21 | 18 | 24 | 28 | 14 | 33 | 9 | 22 | 20 | 15 | 27 | - | - | - | - | - | - | - | - |
| Low | 15 | 9 | 13 | 11 | 17 | 7 | 22 | 2 | 13 | 11 | 14 | 10 | 11 | 13 | - | - | - | - | - | - | - | - | |||
| 9 | Baoshan Cao | 2012 | High | 9 | 8 | 6 | 11 | - | - | 3 | 14 | - | - | 8 | 9 | 17 | 0 | 17 | 0 | 3 | 14 | 1.791 | 0.933–3.438 | 2.067 | 0.649–6.583 |
| Low | 20 | 13 | 13 | 20 | - | - | 17 | 16 | - | - | 15 | 18 | 31 | 2 | 33 | 0 | 14 | 19 | - | - | - | - | |||
| 10 | Jing Wang | 2017 | High | 27 | 27 | - | - | 19 | 35 | - | - | 36 | 18 | 26 | 28 | - | - | - | - | - | - | 2.078 | 1.186–3.641 | 2.623 | 1.229–5.599 |
| Low | 15 | 11 | - | - | 16 | 10 | - | - | 14 | 12 | 10 | 16 | - | - | - | - | - | - | - | - | - | - | |||
| 11 | Shou Yu | 2018 | High | 33 | 39 | 42 | 30 | 30 | 42 | 45 | 27 | - | - | 48 | 24 | 32 | 40 | - | - | - | - | 3.734 | 1.466–9.508 | 0.8 | 0.63–1.01 |
| Low | 27 | 17 | 27 | 17 | 29 | 15 | 37 | 7 | - | - | 34 | 10 | 12 | 32 | - | - | - | - | - | - | - | - | |||
| 12 | Qingkay Li | 2011 | High | - | - | - | 46 | 16 | 8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low | - | - | - | 3 | 27 | 4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |||
| 13 | Ying-Hui Tong | 2017 | High | 116 | 31 | 34 | 98 | 84 | 63 | - | - | 96 | 51 | 77 | 65 | 77 | 60 | - | - | - | - | 1.55 | 1.2–2.01 | - | - |
| Low | 54 | 14 | 13 | 44 | 44 | 24 | - | - | 28 | 40 | 35 | 32 | 24 | 37 | - | - | - | - | - | - | - | - | |||
| 14 | Jueshi Liu | 2018 | High | 19 | 11 | - | - | 24 | 6 | - | - | 9 | 21 | 17 | 13 | 20 | 10 | - | - | - | - | - | - | - | - |
| Low | 27 | 25 | - | - | 20 | 22 | - | - | 26 | 16 | 23 | 19 | 8 | 34 | - | - | - | - | - | - | - | - | |||
| 15 | Yu Xiao | 2018 | High | 38 | 36 | 45 | 29 | 23 | 51 | - | - | - | - | - | - | 60 | 12 | - | - | - | - | 7.505 | 1.656–34.007 | 8.487 | 2.234–32.239 |
| Low | 9 | 21 | 15 | 15 | 7 | 23 | - | - | - | - | - | - | 22 | 6 | - | - | - | - | - | - | - | - | |||
| 16 | Yingxue Zhu | 2018 | High | - | - | - | - | 31 | 37 | - | - | - | - | 39 | 29 | - | - | - | - | - | - | - | - | - | - |
| Low | - | - | - | - | 18 | 6 | - | - | - | - | 14 | 10 | - | - | - | - | - | - | - | - | - | - | |||
| 17 | Manqing Liu | 2018 | High | 58 | 26 | 47 | 37 | - | 92 | - | - | - | - | 29 | 39 | - | - | - | - | - | - | 6.296 | 1.992–19.899 | - | - |
| Low | 31 | 15 | 32 | 14 | - | 38 | - | - | - | - | 19 | 17 | - | - | - | - | - | - | - | - | - | - | |||
| 18 | Ying E | 2019 | High | 26 | 19 | 17 | 28 | 26 | 19 | - | - | - | - | 26 | 19 | 15 | 30 | - | - | - | - | 2.16 | 0.65–7.18 | - | - |
| Low | 15 | 12 | 9 | 18 | 24 | 3 | - | - | - | - | 17 | 10 | 8 | 19 | - | - | - | - | - | - | - | - | |||
| 19 | Hongyan Wang | 2019 | High | 22 | 35 | - | - | - | - | - | - | - | - | - | - | 17 | 40 | - | - | - | - | - | - | - | - |
| Low | 21 | 17 | - | - | - | - | - | - | - | - | - | - | 12 | 26 | - | - | - | - | - | - | - | - | |||
| 20 | Ming-Jen Chen a | 2020 | High | 15 | 17 | 23 | 9 | 20 | 12 | - | - | - | - | 14 | 18 | - | - | - | - | - | - | 1.638 | 1.059–2.535 | 1.676 | 1.074–2.614 |
| Low | 98 | 37 | 68 | 69 | 102 | 33 | - | - | - | - | 54 | 81 | - | - | - | - | - | - | - | - | - | - | |||
| 20' | Ming-Jen Chen b | 2020 | High | 54 | 34 | 55 | 33 | 64 | 24 | - | - | - | - | 35 | 53 | - | - | - | - | - | - | 1.568 | 1.046–2.349 | 1.609 | 0.874–1.533 |
| Low | 59 | 20 | 36 | 45 | 58 | 21 | - | - | - | - | 33 | 46 | - | - | - | - | - | - | - | - | - | - | |||
Abbreviations: SCC: squamous cell carcinomas, AC: adenocarcinomas, OS: overall survival, PFS: progression-free survival, HR: hazard ratio, OR: odds ratio, RR: relative risk, CI: confidence interval, EGFR-TKI: Epidermal growth factor receptor tyrosine kinase inhibitor, CR: complete response, PR: partial response, PD: progression of disease, SD: stable disease.